Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4439341
Max Phase: Preclinical
Molecular Formula: C27H21N3O3
Molecular Weight: 435.48
Molecule Type: Unknown
Associated Items:
ID: ALA4439341
Max Phase: Preclinical
Molecular Formula: C27H21N3O3
Molecular Weight: 435.48
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=c1[nH]c(Nc2ccc(O)cc2)nc(-c2ccccc2)c1Cc1c(O)ccc2ccccc12
Standard InChI: InChI=1S/C27H21N3O3/c31-20-13-11-19(12-14-20)28-27-29-25(18-7-2-1-3-8-18)23(26(33)30-27)16-22-21-9-5-4-6-17(21)10-15-24(22)32/h1-15,31-32H,16H2,(H2,28,29,30,33)
Standard InChI Key: YNBGBNOMFVBXFF-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 435.48 | Molecular Weight (Monoisotopic): 435.1583 | AlogP: 5.34 | #Rotatable Bonds: 5 |
Polar Surface Area: 98.24 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 7.85 | CX Basic pKa: 0.91 | CX LogP: 5.05 | CX LogD: 4.94 |
Aromatic Rings: 5 | Heavy Atoms: 33 | QED Weighted: 0.28 | Np Likeness Score: -0.36 |
1. Botta L, Filippi S, Bizzarri BM, Meschini R, Caputo M, Proietti-De-Santis L, Iside C, Nebbioso A, Gualandi G, Saladino R.. (2019) Oxidative nucleophilic substitution selectively produces cambinol derivatives with antiproliferative activity on bladder cancer cell lines., 29 (1): [PMID:30442421] [10.1016/j.bmcl.2018.11.006] |
Source(1):